Frontlight ResearchEarly access
WithdrawnPhase 1
Mesenchymal Stromal Cells for COVID-19 and Viral Pneumonias
Key facts
- Who runs it
- Medical University of South Carolina
- Where
- Charleston, United StatesSee the site
- Trial code
- Status
- Withdrawn
- Phase
- Phase 1
- Started
- 1 Oct 2024
- Ended
- 1 Oct 2024
- Type of study
- Interventional
- Treatments tested
- Allogeneic Mesenchymal Stromal Cells
- Record updated
- 30 October 2024
- Why it stopped
- Funding
Who can take part
- Age
- 18 years to 80 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 24 criteriaShow less
Who can take part
- Hospitalized with COVID-19 respiratory symptoms and confirmation via COVID-19 SARS-CoV-2 RT-PCR testing
- Patient or their surrogate is willing and able to provide written informed consent and comply with all protocol requirements
- Diagnosis with Mild or Moderate Pneumonia not requiring mechanical ventilation: Patient must have at least one of the following features:; Bilateral pneumonia present on chest radiograph or computed tomography ii. Partial pressure of oxygen/fraction of inspired oxygen (PaO2/FiO2) on arterial blood gas showing: >100mmHg and ≤ 300mmHg regardless of oxygen dose at time of testing; Pulse oxygen saturation (SpO2) at rest ≤ 93% or any degree of hypoxia requiring supplemental oxygen
- Patient agrees to storage of specimens for future testing
- Willingness to undergo mechanical ventilation for worsening
Who cannot take part
- Intubation with mechanical ventilation prior to study enrolment. High flow nasal cannula and non-invasive mechanical ventilation is allowed
- History of long-term use of immunosuppressive agents including prednisone dose >5mg daily over the 30 days prior to enrollment
- Obstructive pneumonia induced by lung cancer or other known causes
- Significant comorbid illness likely to impact the outcome of COVID-19 including but not limited to active malignancy other than skin cancer
- History of severe chronic respiratory disease and requirement for long-term oxygen therapy
- History of moderate and severe liver disease (Child-Pugh score >12)
- History of deep venous thrombosis, pulmonary embolism, cerebral vascular disease within the last 3 years
- Known HIV, hepatitis virus, or syphilis infection
- Co-Infection of tuberculosis, influenza virus, adenovirus and other respiratory infection virus
- Allergy to diphenhydramine, or hydrocortisone
- Any condition unsuitable for the study as determined by the investigators
- Receipt of experimental therapy for COVID-19 with the exception of convalescent plasma, dexamethasone or another corticosteroid, or remdesivir in an open label study
- Estimated or actual rate of creatinine clearance < 15 ml/min
- Pneumonia caused by bacteria, mycoplasma, chlamydia, legionella, fungi or other viruses
- Patients who are participating in other therapeutic clinical trials within 30 days of consent
- Undergoing hemodialysis or peritoneal dialysis
- Substance abuse sufficient that the patient is unlikely to comply with testing requirements
- Moribund patient not expected to survive > 24hours
- Female subjects with positive pregnancy test, breastfeeding, or planning to become pregnant/breastfeed during the study period
Where in United States
- Medical University of South CarolinaCharleston, United States
About the trial
What the trial wants to find out
This is an open-label phase 1 clinical trial of allogeneic umbilical cord derived mesenchymal stromal cells (MSCs) for hospitalized individuals with COVID-19 or other viral pneumonias. Hospitalized individuals who are within 7 days of the onset of a viral pneumonia will be given 2 doses of MSCs at days 1 and 3 after consent. The safety of intravenous infusion will be tested and course of the oxygen response to treatment over 90 days will be evaluated.
The group in the trial
- Allogeneic Mesenchymal Stromal Cell infusionTreatment being tested
Intravenous infusion of 1.25-1.5 x 10\^6 cells/kg with a maximal dose of 100 x 10\^6 cells on days 1 and 3 after study enrollment.
Treatment: Allogeneic Mesenchymal Stromal Cells
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Safety and Tolerability of Allogeneic Umbilical Cord Derived Mesenchymal Stromal Cells (UC-MSCs) to Limit COVID Associated ComplicatioNs: an Open Label, Phase 1 Study in Hospitalized Patients (SAMPSON-1)
- Record updated
- 30 October 2024